Department of Health and Human Services, through National Institutes of Health, awarded Mapp Biopharmaceutical, Inc. of San Diego, CA $1,986,788 under the SBIR program (Phase III), with work starting 2025-09-24 and running to 2028-08-31. It is one of 2 SBIR and STTR awards Mapp Biopharmaceutical, Inc. received in the last two years, $2,281,371 in all. Each figure links to the federal record.
The award
| Recipient | Mapp Biopharmaceutical, Inc. (San Diego, CA) |
|---|---|
| Awarding agency | Department of Health and Human Services |
| Awarding office | National Institutes of Health |
| Phase | Phase III |
| Amount obligated | $1,986,788 |
| Period of performance starts | 2025-09-24 |
| Period of performance ends | 2028-08-31 |
| Award number | SB1AI191871 (grant, CFDA 93.855) |
| Assistance listing | 93.855, Allergy and Infectious Diseases Research |
| Place of performance | San Diego, San Diego County, CA |
| Recipient registry id (UEI) | M9V9QTHR1H28 |
Want the whole picture on Mapp Biopharmaceutical, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Mapp Biopharmaceutical, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Mapp Biopharmaceutical, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
32 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
What it is for
Development of highly potent human monoclonal for rsv immunoprophylaxis - project summary globally, respiratory syncytial virus (rsv) causes over 3 million hospitalizations of neonates/infants. While there are licensed v
Funding actions on this award
| Date | Action | Modification | Amount |
|---|---|---|---|
| 2026-08-25 | Continuation | 000 | $993,435 |
| 2025-09-24 | New | 000 | $993,353 |
Development of highly potent human monoclonal for rsv immunoprophylaxis - project summary globally, respiratory syncytial virus (rsv) causes over 3 million hospitalizations of neonates/infants. While there are licensed vaccines in the u.s. For use in elderly populations, they are neither approved nor appropriate for use in neonates/infants who have immature immune systems. Palivizumab, a prophylactic monoclonal antibody (mab) marketed by astrazeneca and sobi as synagis™, has been available since 1998, but due to high cost and modest efficacy, its use has been restricted to high-risk infants. The recently approved single dose, long-acting mab, nirsevimab (previously known as MEDI8897 and marketed as beyfortus™ by sanofi), has improved efficacy compared to palivizumab and was approved for use in all children up to 24 months of age. However, severe shortages and cost barriers have limited its availability in countries where IT is currently approved (EU, US, japan, australia, canada and china). In october 2023 the CDC issued health alert network CDCHAN-00499 that recommended limiting the use of nirsevimab to higher risk children in the 2023- 2024 season due to the shortages, resulting in many eligible infants not receiving prophylaxis. In addition, nirsevimab is not currently available in any low- or middle-income countries (lmics) and is unavailable in 8/10 of the most populous co ...
From the federal award record.
Other SBIR and STTR awards to Mapp Biopharmaceutical, Inc.
| Starts | Agency | Program | Amount | Project |
|---|---|---|---|---|
| 2025-06-09 | Department of Health and Human Services | SBIR Phase I | $294,583 | A novel cost-effective multispecific therapeutic for dengue - project summary dengue remai (record) |
Every other federal award to Mapp Biopharmaceutical, Inc. on record
The federal register lists 43 or more other awards to the same registry id (UEI M9V9QTHR1H28), $679,019,408 in all, from 2 agencies.
| Starts | Agency | Amount | Award |
|---|---|---|---|
| 2026-02-06 | Defense Health Agency | $20,500 | Procurement of human derived monoclonal antibodies and antigens (HT942626FE011) |
| 2025-09-19 | Defense Health Agency | $60,500 | Human-derived monoclonal antibodies and recombinant antigens (HT942525FE048) |
| 2025-06-06 | Defense Health Agency | $110,500 | Antibody & antigen supply (HT942525F0237) |
| 2024-03-20 | Office of Assistant Secretary for Preparedness and Response | $5,626,972 | Development of medical countermeasures through planned clinical trials and outbreak preparedness (75A50124C00003) |
| 2022-09-30 | Office of Assistant Secretary for Preparedness and Response | $220,916,162 | Procurement of therapeutics for ebola, sudan and marburg viruses (75A50122C00061) |
| 2022-09-28 | Office of Assistant Secretary for Preparedness and Response | $155,212,688 | This cost-plus-fixed-fee contract with mapp biopharmaceutical, inc. (mapp or contractor) is for the developmen (75A50122C00076) |
| 2021-09-30 | Defense Health Agency | $601,142 | Base year for macv contract generates macv IGG2 (W81XWH21C0121) |
| 2020-09-30 | Office of Assistant Secretary for Preparedness and Response | $16,413,163 | Development of a pan-botulinum neurotoxin medical countermeasure (75A50120C00198) |
| 2020-07-28 | Department of the Army | $1,499,004 | STTR Phase II (W911QY20C0099) |
| 2020-06-15 | Defense Contract Management Agency | $1,465,845 | Fundamental research to counter weapons of mass destruction (c-wmd) (HDTRA12010010) |
| 2018-09-25 | Office of Assistant Secretary for Preparedness and Response | $56,704,950 | (75A50118C00024) |
| 2018-09-21 | Department of the Army | $149,999 | STTR Phase I (W911QY18P0299) |
| 2018-01-15 | National Institutes of Health | $2,806,262 | Development of highly potent human monoclonal for rsv immuno-prophylaxis (R44AI136272) |
| 2018-01-15 | National Institutes of Health | $541,451 | Development of highly potent human monoclonals for rsv immunoprophylaxis (R43AI136272) |
| 2017-09-30 | Office of Assistant Secretary for Preparedness and Response | $65,758,722 | (HHSO100201700017C) |
| 2017-09-13 | Office of Assistant Secretary for Preparedness and Response | $7,486,451 | (HHSO100201700023C) |
| 2017-09-01 | Centers for Disease Control and Prevention | $214,693 | Direct sequencing of antibodies of the influenza immune response (R43IP001085) |
| 2017-02-01 | National Institutes of Health | $251,637 | Direct sequencing of serum antibodies after infection (R43AI129082) |
| 2016-08-01 | National Institutes of Health | $219,067 | Rapid response agents against filovirus outbreaks using vectored immunoprophylaxis (R43AI126968) |
| 2016-06-27 | Office of Assistant Secretary for Preparedness and Response | $28,870,288 | Mapp eap - igf::cl::igf for other functionsexpanded access protocol for zmapp (HHSO100201600021C) |
| 2016-05-27 | Department of the Army | $999,928 | SBIR Phase II - monthly status reports (W911QY16C0051) |
| 2015-01-05 | National Institutes of Health | $226,186 | Pseudomonas antibodies with designed glycans (R43AI115840) |
| 2014-09-25 | National Institutes of Health | $224,988 | Novel immunotherapy for brain cancer (R43CA186591) |
| 2014-09-02 | Office of Assistant Secretary for Preparedness and Response | $52,369,282 | For other functions advanced development of zmapp, an ebola virus candidate medical countermeasure (HHSO100201400009C) |
| 2014-07-01 | National Institutes of Health | $551,560 | A human monoclonal for rsv prophylaxis (R43AI114069) |
| 2014-06-11 | Department of the Army | $149,877 | SBIR Phase I (W911QY14P0232) |
| 2014-06-10 | Defense Contract Management Agency | $6,173,324 | Base period - psc: AN12 research and development services (HDTRA114C0115) |
| 2014-04-21 | National Institutes of Health | $5,377,994 | An immunoprotectant for argentine hemorrhagic fever (R01AI111391) |
| 2013-02-15 | Defense Threat Reduction Agency | $11,174,406 | Base year (HDTRA113C0018) |
| 2012-09-07 | National Institutes of Health | $299,986 | A monoclonal cocktail for cdi (R43AI102395) |
Who runs it, who owns it, where the money comes from and what to watch for, every claim linked to its source.
Order Full Report on Mapp Biopharmaceutical, Inc.Look up Mapp Biopharmaceutical, Inc. first. Finding the company and seeing how much is on record uses no credits.
Look up Mapp Biopharmaceutical, Inc.Where this comes from
The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs set aside part of federal research budgets for small companies. Agencies award them in phases: Phase I tests whether an idea is feasible, Phase II funds development, and Phase III is follow-on work paid for outside the set-aside. STTR awards also require a research institution as a partner.
Every figure on this page is taken from the award's own federal record, linked beside it, as it stood when the page was built: the recipient, its address, the awarding agency and office, the amount obligated so far, the dates and the description. Phase and program are shown as the award's own description states them. The amount can grow later if the agency adds funding to the same award.